Search Results - Sterrenberg, Danielle

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Post-Transplantation Lymphoproliferative Disorders: Diagnosis, Prognosis, and Current Approaches to Therapy

    Post-Transplantation Lymphoproliferative Disorders: Diagnosis, Prognosis, and Current Approaches to Therapy by Evens, Andrew M., Roy, Rupali, Sterrenberg, Danielle, Moll, Michelle Z., Chadburn, Amy, Gordon, Leo I.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Abstract PD1-06: Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer

    Abstract PD1-06: Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or m... by Han, Hyo (Heather), Diab, Sami, Alemany, Carlos, Basho, Reva, Brown-Glaberman, Ursa, Meisel, Jane, Pluard, Timothy, Cortes, Javier, Dillon, Patrick, Ettl, Johannes, Kuemmel, Sherko, Sanchez, Luis Manso, Oliveira, Mafalda, O'Shaughnessy, Joyce, Papish, Steven, Sinha, Rajni, Sterrenberg, Danielle, Stringer-Reasor, Erica, Tsai, Michaela, Vazquez, Rafael Villanueva, Wuerstlein, Rachel, Wang, Yinghui, Wang, Zejing, Boni, Valentina

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Busulfan / Melphalan / Bortezomib (Bu-Mel-Vel) Vs. High Dose Melphalan As Conditioning Regimen For Autologous Hematopoietic Cell Transplantation In Multiple Myeloma (MM)

    Busulfan / Melphalan / Bortezomib (Bu-Mel-Vel) Vs. High Dose Melphalan As Conditioning Regimen For Autologous Hematopoietic Cell Transplantation In Multiple Myeloma (MM) by Rodriguez, Tulio E., Hari, Parameswaran, Stiff, Patrick J, Zhong, Xiaobo, Sterrenberg, Danielle, Vesole, David H.

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    High Dose Intravenous Busulfan and Melphalan Followed By Bortezomib (BuMelVel) As Conditioning With Autologous Stem Cell Transplantation (ASCT) For Patients With Multiple Myeloma (MM)

    High Dose Intravenous Busulfan and Melphalan Followed By Bortezomib (BuMelVel) As Conditioning With Autologous Stem Cell Transplantation (ASCT) For Patients With Multiple Myeloma (... by Sterrenberg, Danielle, Stiff, Patrick J, Parthasarathy, Mala, Go, Aileen, Smith, Scott E., Rodriguez, Tulio E.

    Published in Blood
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

    Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma by Rodriguez, Tulio E, Hari, Parameswaran, Stiff, Patrick J, Smith, Scott E, Sterrenberg, Danielle, Vesole, David H

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: